secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001600620-23-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 revenue up 47% to $41.5M; raises FY 2023 guidance to $150-160M
-------------------------------------------------------------------------

- Q2 net revenue $41.5M (+47% YoY); net loss narrowed to $11.5M ($0.08 loss per share) from $35.5M ($0.25).
- Raised FY2023 LUPKYNIS revenue guidance to $150-160M; cited strong commercial execution.
- Patients on therapy reached 1,911 (+50% YoY); patient start forms +10% YoY to 451 in Q2.
- Gross margin 96%; cash and short-term investments $350.7M as of June 30, 2023.
- Initiated strategic review with J.P. Morgan as financial advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/0001600620-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062023000028/auph-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001600620-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer